Sector News

Clariant to acquire Hong Kong-based healthcare packaging firm VitaPac

September 29, 2014
Chemical Value Chain
Clariant’s existing portfolio of packaging solutions. Clariant says that it has signed a purchase agreement to acquire healthcare packaging company VitaPac (Hong Kong). Financial details of the deal were not disclosed. VitaPac, which was founded in 1995, generated sales of about 4 million Swiss francs ($4.2 million) in 2013. VitaPac employs about 80 people and has a production site at Dongguan, China. VitaPac develops and manufactures a full range of protective packaging solutions for the pharmaceutical, neutraceutical and food industries, as well as for the logistics and electronics sectors, mainly in the Asia/Pacific region. The company focuses on active sorbents and has established a leading market position for desiccant packets for moisture adsorption, Clariant says. The transaction is subject to regulatory approvals and is expected to be completed in the fourth quarter of 2014.
 
The bolt-on acquisition of VitaPac complements the portfolio of Clariant’s medical specialties business line within its masterbatches business unit. The deal will help Clariant to gain market share in important emerging markets especially in Asia but also to capture further sales in other regions. The acquired Dongguan plant will enlarge Clariant’s global footprint, furthering the reach to its multinational pharmaceutical customer base, the company says.
 
“The acquisition of VitaPac is in line with our strategy to grow profitably by investing in new technologies and new markets,” says Hariolf Kottmann, CEO of Clariant. “It will enable us to enhance Clariant’s existing portfolio of packaging solutions with new innovative products from the active packaging area, helping us to further develop our positioning in the medical specialties market,” Kottmann says.
 
VitaPac is known for its innovative, technology-driven product lines that address pharmaceutical stability and shelf life, Clariant says. The company maintains a drug master file (DMF) with the US FDA, and its products comply with all pertinent regulations for use in direct contact with food and drugs, Clariant says.
 
By Deepti Ramesh
 

Related News

July 31, 2021

Maire Tecnimont awarded €430-million contract for Repsol’s Portugal polymers expansion 

Chemical Value Chain

The total contract value is approximately €430 million. The project scope of work entails complete engineering services, equipment and material supply, installation and construction activities and, as an optional part of the scope, commissioning and start up.

July 31, 2021

Lenzing invests €23.3 million in new wastewater-treatment plant in the U.K. 

Chemical Value Chain

Once it has implemented this project, Lenzing will have biological wastewater treatment plants that meet the best available techniques (BAT) quality standard at all its production sites.

July 31, 2021

Is hydrogen just oil and gas greenwashed?

Chemical Value Chain

The debate over the position of hydrogen in the new energy revolution has come to the fore again thanks to Japan’s hosting of the Olympic Games. But rather than showcasing how green this miracle new fuel is, it has highlighted its many problems.

Send this to a friend